Verrica Pharma Reports Director Changes & Compensation Updates
Ticker: VRCA · Form: 8-K · Filed: Apr 2, 2025 · CIK: 1660334
| Field | Detail |
|---|---|
| Company | Verrica Pharmaceuticals Inc. (VRCA) |
| Form Type | 8-K |
| Filed Date | Apr 2, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, compensation
TL;DR
Verrica Pharma board shakeup and exec pay changes filed.
AI Summary
Verrica Pharmaceuticals Inc. announced on March 31, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for key personnel. Specific names and dollar amounts related to compensation are not detailed in this excerpt but are indicated as being part of the filing.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, or financial outlook, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can indicate underlying issues or strategic shifts that may affect the company's future performance and stability.
Key Players & Entities
- Verrica Pharmaceuticals Inc. (company) — Registrant
- March 31, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 46-3137900 (ein) — IRS Employer Identification No.
- West Chester, PA (location) — Principal Executive Offices Address
- (484) 453-3300 (phone_number) — Registrant's telephone number
FAQ
What specific items are being reported under the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers' section?
The filing indicates that it reports on the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements of certain officers.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is March 31, 2025.
What is the state of incorporation for Verrica Pharmaceuticals Inc.?
Verrica Pharmaceuticals Inc. is incorporated in Delaware.
What is the principal executive office address for Verrica Pharmaceuticals Inc.?
The principal executive office is located at 44 W. Gay St., Suite 400, West Chester, PA 19380.
What is the SEC file number for Verrica Pharmaceuticals Inc.?
The SEC file number for Verrica Pharmaceuticals Inc. is 001-38529.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 2, 2025 regarding Verrica Pharmaceuticals Inc. (VRCA).